UPDATE
EMF Disturbance Monitors, Inc. will collaborate with Cardiology Research at the University of North Carolina at Chapel Hill to complete the FDA Phase 2 and Phase 3 trials to investigate the ability of our medical device to diagnose advanced congestive heart failure (CHF). Dr. Matthew Cavender will be the Principal Investigator. Patient enrollment is anticipated in the fall of 2025.
SAVING LIVES BY SAVING TIME
EMF Disturbance Monitors has developed a novel medical device platform that measures the strength of the electromagnetic energy field created by organs such as the heart and the brain.
Many human diseases are caused by decreased cellular energy production such as congestive heart failure, cardiomyopathy, traumatic brain injury (TBI), severe depression and dementia. These diseases can be difficult to diagnose using current technology. This can result in a delay in diagnosis that results in irreversible loss of heart of brain cells.
Our solution is an outpatient test that is brief and non-invasive. Early diagnosis of diseases improves patient outcome. We hope to revolutionize the screening process for many diseases that result from low cellular energy production.